rcs research tirzepatide – Peptide RCSB PDB - 7FIM: Cryo-EM

In September 2025, the FDA issued a warning letter addressed to Hims & Hers leadership after reviewing the forhers.com website and identifying compounded semaglutide claims it called false or misleading, including language asserting a weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy and clinically proven ingredients. Now look at the February 2026 weight-loss pill announcement: it describes a compounded semaglutide pill with the same active ingredient as Wegovy. Separately, the FDAs February 2026 enforcement statement again called out the same active ingredient and clinically proven claim types as lines companies cannot cross in promotional materials

But Lilly did not release the underlying data from its trial and the results it disclosed had not been examined by outside experts

Initial shifts can include small but measurable reductions in body weight as your metabolism and hunger signals begin adjusting

Step 3: Personalized Treatment Plan If approved, our providers develop a plan tailored to you

Keep checking back, because we will keep updating this chart based on the lasts research findings and FDA Approvals